Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Other

Abbott Laboratories Corporation

Galapagos Nv

Abbvie S.a.r.l.

Qualcomm Incorporated

Abbott Gmbh & Co Kg

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Shashank Shekhar

George Alan Wiley

Brian Steele

Anthony Ralph Haight

Vincent S Chan

Thaddeus Stephan Franczyk, Ii

Jon James Anderson

David M Barnes

Travis B Dunn

Stevan Wakefield Djuric

Wilfried Martin Braje

Sean Colm Turner

Alan Frank Gasiecki

Irini Akritopoulou-Zanze

Noel S Wilson

Ana-Lucia Relo

Hongyu H Zhao

Dennie S Welch

Min Zhang

Albert Wayne Kruger

Jorge Gandarilla

Huanqiu Li

Christina M Thompson

Philip R Kym

Robert J Altenbach

Xueqing Wang

John R Koenig

Ming Clinton Yeung

Bo Liu

Karine Fabienne Malagu

Sachin V Patel

Xenia Beebe Searle

Marc J Scanio

Andrew Bogdan

David R Hill

Timothy A Grieme

Jianzhang Mei

Maureen Ann McLaughlin

Su Yu

Lei Wang

Thaddeus S Franczyk

Hongyu Zhao

Maureen Ann Mclauglin

Thaddeus S Ii Franczyk

The present invention provides for compounds of formula (I) wherein R, m, Z, G, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Modulators of cystic fibrosis transmembrane conductance regulator protein

The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R, R, R, R, R, A, Y, Y, and Yare as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Modulators of 5-HT receptors and methods of use thereof

This disclosure is directed to: (a) processes for preparing compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compounds and salts; (c) pharmaceutical compositions comprising the compounds or salts; and (d) methods of use of such compositions.

Process for preparing antiviral compounds

The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.

Phosphine ligands for catalytic reactions

The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands.

This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.

Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.

Processes to make apoptosis promoters

Growing community of inventors

Vernon Hills, IL, United States of America

Shashank Shekhar